NO971566L - Method of treating diabetes mellitus using KGF - Google Patents
Method of treating diabetes mellitus using KGFInfo
- Publication number
- NO971566L NO971566L NO971566A NO971566A NO971566L NO 971566 L NO971566 L NO 971566L NO 971566 A NO971566 A NO 971566A NO 971566 A NO971566 A NO 971566A NO 971566 L NO971566 L NO 971566L
- Authority
- NO
- Norway
- Prior art keywords
- kgf
- diabetes mellitus
- treating diabetes
- mammals
- pharmaceutical compositions
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A method and pharmaceutical compositions are described for the use of keratinocyte growth factor to treat diabetes in mammals.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32347594A | 1994-10-13 | 1994-10-13 | |
US32334094A | 1994-10-13 | 1994-10-13 | |
US48782595A | 1995-06-07 | 1995-06-07 | |
PCT/IB1995/000992 WO1996011950A1 (en) | 1994-10-13 | 1995-10-12 | Method of treating diabetes mellitus using kgf |
Publications (2)
Publication Number | Publication Date |
---|---|
NO971566D0 NO971566D0 (en) | 1997-04-04 |
NO971566L true NO971566L (en) | 1997-04-14 |
Family
ID=27406268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19971568A NO318761B1 (en) | 1994-10-13 | 1997-04-04 | Polypeptide Analog to Native Keratinocyte Growth Factor Called "KGF", Pharmaceutical Formulation, Recombinant Nucleic Acid Molecule, Biological Functional Vector, Prokaryotic or Eukaryotic Host Cell, Process for Preparation of an Analog of KGF, Use of an Effective Amount of Invention of the KGF of a drug for stimulating the production of non-fibroblast epithelial cells, in vitro methods for stimulating the production of non-fibroblast epithelial cells, and kits. |
NO971566A NO971566L (en) | 1994-10-13 | 1997-04-04 | Method of treating diabetes mellitus using KGF |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19971568A NO318761B1 (en) | 1994-10-13 | 1997-04-04 | Polypeptide Analog to Native Keratinocyte Growth Factor Called "KGF", Pharmaceutical Formulation, Recombinant Nucleic Acid Molecule, Biological Functional Vector, Prokaryotic or Eukaryotic Host Cell, Process for Preparation of an Analog of KGF, Use of an Effective Amount of Invention of the KGF of a drug for stimulating the production of non-fibroblast epithelial cells, in vitro methods for stimulating the production of non-fibroblast epithelial cells, and kits. |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP0785948B1 (en) |
JP (2) | JP4426646B2 (en) |
KR (1) | KR100278597B1 (en) |
CN (1) | CN1168678A (en) |
AT (2) | ATE237633T1 (en) |
AU (1) | AU3707795A (en) |
BG (2) | BG101392A (en) |
BR (2) | BR9509269A (en) |
CA (2) | CA2202075C (en) |
CZ (3) | CZ297329B6 (en) |
DE (2) | DE69530403T2 (en) |
DK (2) | DK0785948T3 (en) |
EE (2) | EE9700225A (en) |
ES (2) | ES2273338T3 (en) |
FI (2) | FI971420A (en) |
HU (2) | HUT78050A (en) |
NO (2) | NO318761B1 (en) |
NZ (2) | NZ505502A (en) |
PL (2) | PL320484A1 (en) |
PT (2) | PT785948E (en) |
SI (2) | SI0804479T1 (en) |
SK (2) | SK43197A3 (en) |
WO (2) | WO1996011950A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0555205B1 (en) | 1989-01-31 | 2000-11-29 | RUBIN, Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
PT706563E (en) | 1993-06-29 | 2005-01-31 | Chiron Corp | TRUNCATED KERATINOCYTE GROWTH FACTOR (KGF) WITH INCREASED BIOLOGICAL ACTIVITY |
US7084119B2 (en) | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
ES2197926T3 (en) * | 1994-10-13 | 2004-01-16 | Amgen Inc. | METHOD TO PURIFY FACTORS OF GROWTH OF KERATINOCITS. |
US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
US6077692A (en) * | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
EP0822943B9 (en) * | 1995-04-27 | 2007-02-28 | Coöperatie Cosun U.A. | Inulin derivatives |
SI0935652T1 (en) * | 1996-10-15 | 2004-06-30 | Amgen Inc. | Keratinocyte growth factor-2 products |
US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
JP2001506975A (en) * | 1996-10-15 | 2001-05-29 | アムジェン インコーポレイテッド | Keratinocyte growth factor-2 product |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
ATE375363T1 (en) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | GROWTH HORMONE DERIVATIVES AND RELATED PROTEINS |
US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
CA2316015A1 (en) | 1997-12-22 | 1999-07-01 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
US6242666B1 (en) | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
IL144259A0 (en) * | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US6248725B1 (en) | 1999-02-23 | 2001-06-19 | Amgen, Inc. | Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction |
CN1491231A (en) * | 2001-02-06 | 2004-04-21 | Ĭ��ר������˾ | Modified keratinocyte growth factor (KGF) with reduced immunogenicity |
US7265089B2 (en) | 2001-08-21 | 2007-09-04 | Chiron Corporation | KGF polypeptide compositions |
AU2007214362B2 (en) * | 2001-08-21 | 2009-11-26 | Novartis Vaccines And Diagnostics, Inc. | KGF polypeptide compositions |
SI1827483T1 (en) | 2004-12-15 | 2014-11-28 | Swedish Orphan Biovitrum Ab (Publ) | Therapeutic formulations of keratinocyte growth factor |
CN102242124B (en) * | 2010-05-10 | 2013-05-22 | 齐鲁制药有限公司 | Modified Keratinocyte growth factor gene and its expression in yeast |
KR102440312B1 (en) * | 2020-08-28 | 2022-09-05 | 한국해양과학기술원 | Thermally stable fgf7 polypeptide and use of the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
JPH01137994A (en) * | 1987-08-10 | 1989-05-30 | Shionogi & Co Ltd | Reg protein |
CA1306456C (en) * | 1988-07-27 | 1992-08-18 | Marjan International Pty. Ltd. | Carpet stretcher |
EP0555205B1 (en) * | 1989-01-31 | 2000-11-29 | RUBIN, Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
JP3303211B2 (en) * | 1991-04-26 | 2002-07-15 | 武田薬品工業株式会社 | bFGF mutein and method for producing the same |
CN1064710C (en) * | 1993-03-26 | 2001-04-18 | 安姆根有限公司 | Therapeutic uses of keratinocyte growth factor |
PT706563E (en) * | 1993-06-29 | 2005-01-31 | Chiron Corp | TRUNCATED KERATINOCYTE GROWTH FACTOR (KGF) WITH INCREASED BIOLOGICAL ACTIVITY |
US5348563A (en) * | 1993-06-29 | 1994-09-20 | Honeywell Inc. | Air purifying apparatus |
GB9315501D0 (en) * | 1993-07-27 | 1993-09-08 | Ici Plc | Surfactant compositions |
EP0712314A1 (en) * | 1993-08-02 | 1996-05-22 | Prizm Pharmaceuticals, Inc. | Monogenous preparations of cytotoxic conjugates |
-
1995
- 1995-10-12 CA CA002202075A patent/CA2202075C/en not_active Expired - Fee Related
- 1995-10-12 CZ CZ20023953A patent/CZ297329B6/en not_active IP Right Cessation
- 1995-10-12 EP EP95934793A patent/EP0785948B1/en not_active Expired - Lifetime
- 1995-10-12 ES ES95934808T patent/ES2273338T3/en not_active Expired - Lifetime
- 1995-10-12 KR KR1019970702343A patent/KR100278597B1/en not_active IP Right Cessation
- 1995-10-12 PT PT95934793T patent/PT785948E/en unknown
- 1995-10-12 CZ CZ0105097A patent/CZ297328B6/en not_active IP Right Cessation
- 1995-10-12 JP JP51307696A patent/JP4426646B2/en not_active Expired - Fee Related
- 1995-10-12 DE DE69530403T patent/DE69530403T2/en not_active Expired - Lifetime
- 1995-10-12 NZ NZ505502A patent/NZ505502A/en not_active IP Right Cessation
- 1995-10-12 AU AU37077/95A patent/AU3707795A/en not_active Abandoned
- 1995-10-12 SI SI9530728T patent/SI0804479T1/en unknown
- 1995-10-12 SK SK431-97A patent/SK43197A3/en unknown
- 1995-10-12 SK SK455-97A patent/SK284534B6/en not_active IP Right Cessation
- 1995-10-12 WO PCT/IB1995/000992 patent/WO1996011950A1/en active IP Right Grant
- 1995-10-12 SI SI9530654T patent/SI0785948T1/en unknown
- 1995-10-12 HU HU9901071A patent/HUT78050A/en unknown
- 1995-10-12 DK DK95934793T patent/DK0785948T3/en active
- 1995-10-12 BR BR9509269A patent/BR9509269A/en not_active Application Discontinuation
- 1995-10-12 EP EP95934808A patent/EP0804479B1/en not_active Expired - Lifetime
- 1995-10-12 DK DK95934808T patent/DK0804479T3/en active
- 1995-10-12 DE DE69535264T patent/DE69535264T2/en not_active Expired - Lifetime
- 1995-10-12 WO PCT/IB1995/000971 patent/WO1996011949A2/en active IP Right Grant
- 1995-10-12 EE EE9700225A patent/EE9700225A/en unknown
- 1995-10-12 CZ CZ97981A patent/CZ98197A3/en unknown
- 1995-10-12 PL PL95320484A patent/PL320484A1/en unknown
- 1995-10-12 AT AT95934793T patent/ATE237633T1/en active
- 1995-10-12 HU HU9901255A patent/HU226168B1/en not_active IP Right Cessation
- 1995-10-12 BR BR9509329A patent/BR9509329A/en not_active Application Discontinuation
- 1995-10-12 CA CA002201940A patent/CA2201940C/en not_active Expired - Fee Related
- 1995-10-12 CN CN95196410A patent/CN1168678A/en active Pending
- 1995-10-12 AT AT95934808T patent/ATE342278T1/en active
- 1995-10-12 ES ES95934793T patent/ES2196082T3/en not_active Expired - Lifetime
- 1995-10-12 PT PT95934808T patent/PT804479E/en unknown
- 1995-10-12 JP JP51307796A patent/JP4216329B2/en not_active Expired - Fee Related
- 1995-10-12 PL PL95319784A patent/PL182888B1/en not_active IP Right Cessation
- 1995-10-12 EE EE9700081A patent/EE03975B1/en not_active IP Right Cessation
-
1997
- 1997-04-04 NO NO19971568A patent/NO318761B1/en not_active IP Right Cessation
- 1997-04-04 FI FI971420A patent/FI971420A/en unknown
- 1997-04-04 NO NO971566A patent/NO971566L/en unknown
- 1997-04-07 BG BG101392A patent/BG101392A/en unknown
- 1997-04-11 FI FI971536A patent/FI120040B/en not_active IP Right Cessation
- 1997-04-11 BG BG101408A patent/BG63167B1/en unknown
-
1999
- 1999-04-09 NZ NZ335109A patent/NZ335109A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO971566L (en) | Method of treating diabetes mellitus using KGF | |
AU8163398A (en) | Inhibitors of alpha4beta1mediated cell adhesion | |
NO20056021L (en) | Use of CS-866 in the manufacture of a medicament | |
DE69132048T2 (en) | Use of steroids to inhibit angiogenesis | |
AU2209500A (en) | Inhibitors of alpha4beta1 mediated cell adhesion | |
MX9704050A (en) | New dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals. | |
NO982229L (en) | Sulfur-containing di-tert-butylphenol compounds useful as anti-inflammatory agents | |
MD960168A (en) | Method for treatment of viral infections and compounds therefor | |
GEP20012511B (en) | Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis | |
SE9400524D0 (en) | energy Preparations | |
ATE306278T1 (en) | TREATING BONE DISEASES WITH ADRENOMEDULLIN | |
DE69110861D1 (en) | AGENTS FOR IMPROVING AND USING COLLAGEN METABOLISM. | |
AUPM836794A0 (en) | Improved method and composition for the treatment of ulcers | |
ATE315583T1 (en) | ANALOGUE OF THYMOSINE ALPHA 1 | |
UA15363A (en) | Composition for treating open wounds |